DGAP-News: Xenikos B.V. / Key word(s): Change of Personnel
Xenikos appoints Eric van Hooren as Chief Development Officer to drive
forward T-Guard(TM) clinical development program
02.11.2016 / 12:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Xenikos appoints Eric van Hooren as Chief Development Officer to drive
forward T-Guard(TM) clinical development program
Nijmegen, the Netherlands, November 2nd, 2016 - Xenikos B.V., focused on
the development of innovative immunotherapies for the treatment of patients
suffering from serious immune diseases or rejection after transplantation,
announced today that it has hired Eric van Hooren as Chief Development
Officer (CDO).
Mr. van Hooren has over 20 years of experience in the pharmaceutical
industry, including extensive work in clinical project and clinical trial
management. Prior to joining Xenikos, he was Director Clinical Operations
at Acerta-Pharma, where he was responsible for the set up and line
management of the European clinical operations group, including the
execution of Phase 1, 2 and 3 clinical trial programs with the compound
acalabrutinib, a potential best-in-class irreversible oral Bruton's
tyrosine kinase (BTK) inhibitor, that contributed to a major transaction
with AstraZeneca in December 2015. Mr. van Hooren previously worked as a
Program Manager at Merck, where he managed Women's Health Programs. He also
worked for many years at Organon in positions of increasing responsibility
in both clinical development and medical marketing.
At Xenikos, Mr. van Hooren will be responsible for preparing and executing
the EU/US randomized active-controlled Phase 2 pivotal study of T-Guard in
acute graft-versus-host disease (GVHD), as well as exploring new potential
indications that might benefit from T-Guard's promise as a therapeutic tool
for safely and swiftly resetting the body's immune system in T-cell-
mediated diseases. He will take over the responsibilities of Dr. Edna
Venneker, who is leaving the company to pursue another opportunity.
Xenikos announced just recently that the last patient has completed
treatment in the Company's Phase 1/2 trial evaluating T-Guard for the
treatment of steroid-resistant acute graft-versus-host disease (GVHD). Ypke
van Oosterhout, PhD, Chief Executive Officer, said: "We are delighted to
welcome Eric to Xenikos in this very important phase of the T-Guard
development. He has a broad background in strategic drug development for
both new biological and new chemical entities, as well as in global
clinical trial management and medical marketing. His many years of
experience will be invaluable as we continue to advance our product
candidate, T-Guard in clinical development and eventual registration for
market approval in acute graft-versus-host disease, as well as explore
other opportunities for this promising development candidate." Dr. van
Oosterhout continued: "I would also like to warmly thank Dr. Venneker, who
has been instrumental in driving our clinical program. We wish her the very
best in her next endeavor."
About Xenikos B.V.
Xenikos B.V. is developing new, innovative immunotherapies to help restore
patients' health and save lives. It is developing new therapies based on
the action of conjugated antibodies that enables patients suffering from
serious immune diseases or rejection after transplantation to reset their
immune systems quickly and efficiently. Its lead product candidate T-
Guard(TM) is currently being developed for the second-line treatment of
steroid-resistant acute GVHD. Further information is available at
www.xenikos.com.
For further information, please contact:
<pre>
Corporate contact: Media contact:
Xenikos B.V. MC Services AG
Ypke van Oosterhout Dr. Solveigh Mähler
Chief Executive Officer Phone: +49 211 529 252 19
Phone: +31 24 3000100 Email: solveigh.maehler@mc-services.eu
Mobile: +31 6 11017611
Email: y.vanoosterhout@xenikos.com For US inquiries:
Laurie Doyle
Phone: +1 339 832 0752
Email: laurie.doyle@mc-services.eu
</pre>
---------------------------------------------------------------------------
02.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
516459 02.11.2016
DGAP-News: Xenikos appoints Eric van Hooren as Chief Development Officer to drive forward T-Guard(TM) clinical development program
| Quelle: EQS Group AG